

Sensimed AG Raises 10 Million CHF in Series B Financing

Lausanne, Switzerland, May 25th, 2010 – Sensimed AG, a Swiss company with its principal focus on design, development, and commercialization of integrated micro-systems for medical devices, announced today the closing of a CHF10M Series B financing co-led by Wellington Partners and Vinci Capital – Renaissance PME. The round was completed by current investor Blue Ocean Ventures, and by private and strategic investors. SpringBay Partners acted as lead advisor for Sensimed on this private equity placement.

The company has developed the SENSIMED Triggerfish®, a revolutionary tool for continuous monitoring of fluctuations in intra-ocular pressure for the management of related diseases such as glaucoma.

Funds will be used to achieve approval in the US and in Asian countries, to commercialize the CE-marked device in selected geographies, to run post-marketing application trials and to fund ongoing operations.

“This round of financing is an important validation of the potential of our technology,” says Jean-Marc Wismer. “Furthermore, new strategic investors will be a strong asset for the development of the company in Asia and in the Middle East”.

Says Erich Schlick, general partner with Wellington Partners: “Sensimed has made great progress in the past two years with its breakthrough technology for the benefit of glaucoma patients; Wellington is looking forward to further supporting on-going development”.

Besides the significant investment in Sensimed AG, Handok Pharmaceuticals will support Sensimed AG with clinical trials, regulatory processes and distribution in South Korea. Says Young-Jin Kim, CEO and Chairman of Handok Pharmaceuticals: “There are strong synergies between our two companies as we intend to expand our activities to ophthalmology”.

“Sensimed is a promising investment. We see a strong potential for this product and look forward to introducing the SENSIMED Triggerfish® in the Middle East”, says Walid Hanna, managing partner of Medholdings SA.

Private investors include Patrick Berdoz, a serial entrepreneur who recently sold Precimed SA, will join the board of directors. “I am impressed by the progress made so far and look forward to working with the management team to expand this promising technology into new markets” says Berdoz.

Further information about Sensimed AG is available on www.sensimed.ch

About Wellington Partners

Wellington Partners ranks among the most successful pan-European venture capital firms. With currently €800 million under management, the firm invests into opportunities throughout Europe that have the potential to become global leaders, mainly in the areas of Information Technology, Media Convergence and Life Sciences. Since 1991, Wellington has

established a worldwide network to support its entrepreneurs in building companies on a global scale. Wellington Partners has invested in more than 100 companies in Europe and Israel, including publicly traded Actelion, Wavelight and XING, successful privately held companies like Alando (acquired by eBay) and Grandis (acquired by Novartis) as well as current portfolio companies like immatics, mtm laboratories, Oxford Immunotech and Supersonic Imagine. For further information please visit www.wellington-partners.com

About Vinci Capital

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 Vinci Capital has provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts. Vinci Capital has an exclusive mandate to manage the funds of Renaissance PME and Mona Lisa AG. Renaissance PME is a foundation dedicated to Swiss pension funds to provide them with a fiscally-optimized and regulated vehicle for direct private-equity investments. Mona Lisa AG is an investment holding funded by Swisscom dedicated to financing innovative Swiss SMEs with high growth potential. For further information please visit www.renaissance-pme.ch and www.vincicapital.ch

About BlueOcean Ventures

BlueOcean Ventures is providing capital, operating and other value adding resources to entrepreneurs in Switzerland and neighboring region. BlueOceans's privileged access to Swiss Technology Centers of excellence helps identify at an early stage the best hi-tech hi-growth investment opportunities. Funds are provided by Private individuals attracted by the potential and reputation of Swiss-made products and achievements and Family offices eager to benefit from a high-return asset category in a safer-than-usual environment. BlueOcean Ventures has offices in Geneva (Switzerland). For further information please visit www.blueocean-ventures.com

Contact details:

SENSIMED AG
Jean-Marc Wismer
CEO
T. +41 78 636-2951
E. jean-marc_wismer@sensimed.ch